CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
重定向工程化人嵌合抗原受体（CAR）T 细胞的制备
英文原题：Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.
查看英文原题
Generation of Redirected Engineered Human Chimeric Antigen Receptor (CAR) T Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法通过基因工程改造患者自身免疫细胞，使其表达抗原特异性受体，在血液癌症治疗中展现出显著疗效。多项靶向血细胞表面蛋白CD19的CAR-T 细胞临床研究促成FDA首次批准基因工程细胞疗法。制备有效CAR-T 细胞涉及多个需谨慎执行的制造步骤。本文介绍用于临床前研究的重定向工程化人CAR-T 细胞制备方法，涵盖CAR设计、逆转录病毒基因转移、CAR表达检测及转导T细胞扩增。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy that involves genetic engineering a patient's own immune cells with antigen-specific receptors has shown remarkable efficacy in blood cancer treatment. Numerous clinical studies with CAR T cells targeting the blood cell surface protein CD19 led to the FDA 's first approval of a genetically engineered cell therapy. The process of generating potent CAR T cells involves several carefully performed manufacturing steps.
Here, we describe the generation of redirected engineered human CAR T cells for preclinical studies starting with the CAR design, retroviral gene transfer, detection of CAR expression, and expansion of transduced T cells.
论文信息
- 作者
- Bunse M、Höpken UE
- 第一作者单位
- Department of Microenvironmental Regulation in Autoimmunity and Cancer, Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany.Germany
- 通讯作者单位
- Department of Microenvironmental Regulation in Autoimmunity and Cancer, Max-Delbrück-Center for Molecular Medicine (MDC), Berlin, Germany. uhoepken@mdc-berlin.de.Germany
- 期刊
- Methods in molecular biology (Clifton, N.J.)2022
- 原文标识
- PubMed 35732993 · DOI 10.1007/978-1-0716-2441-8_4